RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Effects of Alprazolam and Imipramine on Parasympathetic Cardiac Control in Patients with Generalized Anxiety Disorder
Mcleod, DR., Hoehnsaric, R., Porges, S., & Zimmerli, WD. (1992). Effects of Alprazolam and Imipramine on Parasympathetic Cardiac Control in Patients with Generalized Anxiety Disorder. Psychopharmacology, 107(4), 535-540. https://doi.org/10.1007/BF02245268
A noninvasive measure was used to assess the effects of alprazolam, imipramine and placebo on parasympathetic (vagal) cardiac control following 6-weeks of medication in patients with generalized anxiety disorder, Flexible dosage at therapeutic levels resulted in increased heart rate and blood pressure and in decreased cardiac vagal control in patients receiving imipramine but not alprazolam or placebo, About 50% of the variance in heart rate changes and changes in mean arterial blood pressure following treatment with imipramine could be accounted for by changes in cardiac vagal control. Decreased cardiac vagal control can now be added to the list of cardiovascular changes seen following several weeks of treatment with imipramine